Apilimod

Drug Profile

Apilimod

Alternative Names: Apilimod mesylate; STA-5326; STA-5326 mesylate

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Synta Pharmaceuticals
  • Developer Madrigal Pharmaceuticals; Synta Pharmaceuticals
  • Class Antirheumatics; Hydrazines; Morpholines; Pyrimidines; Small molecules
  • Mechanism of Action Interleukin 12 inhibitors; Interleukin 23 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Rheumatoid arthritis
  • Discontinued Common variable immunodeficiency; Crohn's disease; Psoriasis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in USA (Parenteral)
  • 15 Dec 2016 Biomarkers information updated
  • 22 Jul 2016 Madrigal Pharmaceuticals merged with Synta Pharmaceuticals and the combined company is now called as Madrigal Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top